MiNK Therapeutics (INKT) to Release Quarterly Earnings on Tuesday

MiNK Therapeutics (NASDAQ:INKT) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

MiNK Therapeutics Price Performance

INKT stock opened at $8.49 on Monday. The stock has a market capitalization of $33.65 million, a price-to-earnings ratio of -2.18 and a beta of 0.16. The business’s fifty day moving average price is $8.94 and its two-hundred day moving average price is $7.74. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $19.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their price objective on MiNK Therapeutics from $9.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.